Skip to main content
TipRanks
Go Ultimate75% OFF

Clinuvel Pharmaceuticals (CLVLF) Stock Price & Analysis

42 Followers

CLVLF Stock Chart & Stats

$4.82-$0.05(-1.03%)
At close: 4:00 PM EST
$5$6$7Aug 19Aug 31Sep 4Sep 25Oct 7Oct 23
Day’s Range
$4.54 - $5.09
52-Week Range
$4.53 - $8.93
Previous Close
$4.87
Volume
N/A
Average Volume (3M)
1,262
Market Cap
$243.15M
Enterprise Value
$272.15M
Total Cash (Recent Filing)
$252.06M
Total Debt (Recent Filing)
$1.94M
Price to Earnings (P/E)
10.6
Beta
0.06
Next Earnings
Feb 23, 2027 (Est.)
Dividend Yield
0.75%

Bulls Say, Bears Say

Bulls Say

Profitable SCENESSE Franchise

A decade of uninterrupted profitability demonstrates a proven commercial model and reduces dependence on unvalidated future products. Record SCENESSE treatment volumes and revenue above AUD 100 million provide an established earnings base that can support continued investment and expansion over the next several years.

Debt-free Balance Sheet And Cash Generation

Substantial cash reserves and a debt-free balance sheet give Clinuvel financial flexibility to fund clinical development, infrastructure and commercialization without relying on external financing. This strengthens resilience during market or development setbacks and preserves management’s ability to invest for durable growth.

R&D Pipeline And Platform Expansion

Material reinvestment in multiple programs creates opportunities to broaden the company beyond its established EPP franchise. Progress in vitiligo, NEURACTHEL and the controlled-release peptide platform could add future products and expand the addressable market, while the Singapore facility increases development capacity.

Bears Say

Revenue And Margin Deterioration

The return to negative revenue growth and the pronounced gross-margin reset indicate that recent earnings quality is weaker than the historical trend. If this reflects pricing, product mix or cost pressure rather than a temporary fluctuation, it could constrain profitability and reduce funds available for pipeline investment.

Competitive Pressure In EPP

Free competing treatments can delay or displace SCENESSE use and make patient acquisition more difficult in the U.S., even if the pressure is linked to clinical trials. Continued competition could limit treatment-volume growth and require greater commercial effort to protect the established EPP franchise.

Long And Uncertain Regulatory Timelines

The extended CUV107 timetable delays clarity on the vitiligo opportunity and keeps future expansion dependent on lengthy clinical and regulatory execution. Additional FDA education and engagement add uncertainty to approval timing, potentially postponing diversification beyond SCENESSE for several years.

Clinuvel Pharmaceuticals News

CLVLF FAQ

What was Clinuvel Pharmaceuticals ’s price range in the past 12 months?
Clinuvel Pharmaceuticals lowest stock price was $4.53 and its highest was $8.93 in the past 12 months.
What is Clinuvel Pharmaceuticals ’s market cap?
Clinuvel Pharmaceuticals ’s market cap is $243.15M.
When is Clinuvel Pharmaceuticals ’s upcoming earnings report date?
Clinuvel Pharmaceuticals ’s next earnings report is estimated for Feb 23, 2027 (not yet confirmed), which is in 95 days.
How were Clinuvel Pharmaceuticals ’s earnings last quarter?
Clinuvel Pharmaceuticals released its earnings results on Aug 27, 2026. The company reported $0.322 earnings per share for the quarter, missing the consensus estimate of $0.343 by -$0.021.
Is Clinuvel Pharmaceuticals overvalued?
According to Wall Street analysts Clinuvel Pharmaceuticals ’s price is currently Undervalued.
Does Clinuvel Pharmaceuticals pay dividends?
Clinuvel Pharmaceuticals pays an annual dividend of $0.036 which represents an annual dividend yield of 0.75%. See more information on Clinuvel Pharmaceuticals dividends here
What is Clinuvel Pharmaceuticals ’s EPS estimate?
Clinuvel Pharmaceuticals ’s EPS estimate is 0.17.
How many shares outstanding does Clinuvel Pharmaceuticals have?
Clinuvel Pharmaceuticals has 50,487,125 shares outstanding.
What happened to Clinuvel Pharmaceuticals ’s price movement after its last earnings report?
Clinuvel Pharmaceuticals reported an EPS of $0.322 in its last earnings report, missing expectations of $0.343. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Clinuvel Pharmaceuticals ?
Currently, no hedge funds are holding shares in CLVLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology